keyword
MENU ▼
Read by QxMD icon Read
search

erythropoiesis review

keyword
https://www.readbyqxmd.com/read/27922585/are-erythropoiesis-stimulating-agents-beneficial-for-anemia-in-chronic-heart-failure-patients
#1
Diego Araneda, Gabriel Rada
Anemia is a common comorbidity among patients with chronic health failure and appears to be associated with increased mortality and morbidity. However, it is unclear whether correcting it with erythropoiesis stimulating agents improves clinical outcomes. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified 11 systematic reviews including 17 trials overall addressing the question of this article. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach...
November 23, 2016: Medwave
https://www.readbyqxmd.com/read/27900772/hematopoietic-stem-cell-transplantation-for-people-with-%C3%A3-thalassaemia-major
#2
REVIEW
Vanitha A Jagannath, Zbys Fedorowicz, Amani Al Hajeri, Akshay Sharma
BACKGROUND: Thalassemia is an inherited autosomal recessive blood disorder, caused by mutations in globin genes or their regulatory regions. This results in a reduced rate of synthesis of one of the globin chains that make up haemoglobin. In ß-thalassaemia major there is an underproduction of ß-globin chains combined with excess of free α-globin chains. The excess free α-globin chains precipitate in red blood cells, leading to their destruction (haemolysis) and ineffective erythropoiesis...
November 30, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27890361/iron-dysregulation-in-beta-thalassemia
#3
REVIEW
Kamonlak Leecharoenkiat, Pathrapol Lithanatudom, Wannapa Sornjai, Duncan R Smith
Iron deficiency anemia and iron overload conditions affect more than one billion people worldwide. Iron homeostasis involves the regulation of cells that export iron into the plasma and cells that utilize or store iron. The cellular iron balance in humans is primarily mediated by the hepcidin-ferroportin axis. Ferroportin is the sole cellular iron export protein, and its expression is regulated transcriptionally, post-transcriptionally and post-translationally. Hepcidin, a hormone produced by liver cells, post-translationally regulates ferroportin expression on iron exporting cells by binding with ferroportin and promoting its internalization by endocytosis and subsequent degradation by lysosomes...
November 2016: Asian Pacific Journal of Tropical Medicine
https://www.readbyqxmd.com/read/27867951/red-cell-distribution-width-and-cancer
#4
REVIEW
Martina Montagnana, Elisa Danese
Red cell distribution width (RDW) is an index which primarily reflects impaired erythropoiesis and abnormal red blood cell survival. In last years the interest in this marker has considerably grown and now a lot of data are available indicating that this simple and inexpensive parameter is a strong and independent risk factor for death in the general population. Moreover, several investigations have been performed to investigate the role of RDW in cardiovascular and thrombotic disorders. Contrarily, there are relatively few reports focusing on RDW in the area of oncology and to date none review have been performed in this specific field...
October 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27851834/a-regulatory-function-of-long-non-coding-rnas-in-red-blood-cell-development
#5
Klaudia Kulczyńska, Mirosława Siatecka
In recent years it has been discovered that long non-coding RNAs are important regulators in many biological processes. In this review, we summarize the role of lncRNA in erythropoiesis. LncRNA are crucial for regulation of gene expression during both, proliferation and differentiation stages of red blood cell development. Many are regulated by erythroid-specific transcription factors and some are expressed in a developmental stage-specific manner. The majority of individually studied lncRNAs are involved in regulating the terminal maturation stages of red cell differentiation...
November 17, 2016: Acta Biochimica Polonica
https://www.readbyqxmd.com/read/27826644/novel-faces-of-fibroblast-growth-factor-23-fgf23-iron-deficiency-inflammation-insulin-resistance-left-ventricular-hypertrophy-proteinuria-and-acute-kidney-injury
#6
Mehmet Kanbay, Marc Vervloet, Mario Cozzolino, Dimitrie Siriopol, Adrian Covic, David Goldsmith, Yalcin Solak
FGF23 is a hormone that appears as the core regulator of phosphate metabolism. Great deal of data has accumulated to demonstrate increased FGF23 secretion from the bone to compensate for even subtle increases in serum phosphorus long before intact PTH. However, recent evidence points to the fact that actions and interactions of FGF23 are not limited solely to phosphate metabolism. FGF23 may be implicated in iron metabolism and erythropoiesis, inflammation, insulin resistance, proteinuria, acute kidney injury and left ventricular hypertrophy...
November 9, 2016: Calcified Tissue International
https://www.readbyqxmd.com/read/27801605/fetal-hemoglobin-regulation-in-%C3%AE-thalassemia-heterogeneity-modifiers-and-therapeutic-approaches
#7
Orapan Sripichai, Suthat Fucharoen
Stress erythropoiesis induces fetal hemoglobin (HbF) expression in β-thalassemias, however the level of expression is highly variable. The last decade has seen dramatic advances in our understanding of the molecular regulators of HbF production and the genetic factors associated with HbF levels, leading to the promise of new methods of the clinical induction of HbF. Areas covered: This article will review the heterogeneity and genetic modifiers of HbF and HbF induction therapy in β-thalassemia. Expert commentary: One promising curative β-thalassemia therapy is to induce HbF synthesis in β-thalassemic erythrocytes to therapeutic levels before clinical symptom occurs...
December 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/27775788/local-bone-marrow-renin-angiotensin-system-in-the-genesis-of-leukemia-and-other-malignancies
#8
I C Haznedaroglu, U Y Malkan
The existence of a local renin-angiotensin system (RAS) specific to the hematopoietic bone marrow (BM) microenvironment had been proposed two decades ago. Most of the RAS molecules including ACE, ACE2, AGT, AGTR1, AGTR2, AKR1C4, AKR1D1, ANPEP, ATP6AP2, CMA1, CPA3, CTSA, CTSD, CTSG, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP21A2, DPP3, EGFR, ENPEP, GPER, HSD11B1, HSD11B2, IGF2R, KLK1, LNPEP, MAS1, MME, NR3C1, NR3C2, PREP, REN, RNPEP, and THOP1 are locally present in the BM microenvironment. Local BM RAS peptides control the hematopoietic niche, myelopoiesis, erythropoiesis, thrombopoiesis and the development of other cellular lineages...
October 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/27774434/fatal-liver-and-bone-marrow-toxicity-by-combination-treatment-of-dichloroacetate-and-artesunate-in-a-glioblastoma-multiforme-patient-case-report-and-review-of-the-literature
#9
Martin Uhl, Stefan Schwab, Thomas Efferth
A 52-year-old male patient was treated with standard radiochemotherapy with temozolomide for glioblastoma multiforme (GBM). After worsening of his clinical condition, further tumor-specific treatment was unlikely to be successful, and the patient seeked help from an alternative practitioner, who administered a combination of dichloroacetate (DCA) and artesunate (ART). A few days later, the patient showed clinical and laboratory signs of liver damage and bone marrow toxicity (leukopenia, thrombocytopenia). Despite successful restoration of laboratory parameters upon symptomatic treatment, the patient died 10 days after the infusion...
2016: Frontiers in Oncology
https://www.readbyqxmd.com/read/27769353/erythropoiesis-provides-a-brd-s-eye-view-of-bet-protein-function
#10
REVIEW
Aaron J Stonestrom, Sarah C Hsu, Michael T Werner, Gerd A Blobel
Pharmacologic inhibitors of the bromodomain and extra-terminal motif (BET) protein family are in clinical trials for the treatment of hematologic malignancies, yet the functions of individual BET proteins remain largely uncharacterized. We review the molecular roles of BETs in the context of erythropoiesis. Studies in this lineage have provided valuable insights into their mechanisms of action, and helped define the individual and overlapping functions of BET protein family members BRD2, BRD3, and BRD4. These studies have important ramifications for our understanding of the molecular and physiologic roles of BET proteins, and provide a framework for elucidating some of the beneficial and adverse effects of pharmacologic inhibitors...
March 2016: Drug Discovery Today. Technologies
https://www.readbyqxmd.com/read/27750487/the-relationship-between-serum-total-testosterone-and-free-testosterone-levels-with-serum-hemoglobin-and-hematocrit-levels-a-study-in-1221-men
#11
Yu Seob Shin, Jae Hyung You, Jai Seong Cha, Jong Kwan Park
OBJECTIVE: To investigate the relationship between serum total testosterone (TT) and free testosterone (FT) levels in men with anemia. METHODS: We reviewed the records of 1221 subjects between March 2009 and December 2014. All the subjects' blood samples were drawn for TT and FT assays. Their serum hemoglobin (Hb) and serum hematocrit (Hct) levels were measured. The primary objective of our study was to investigate the association between TT and FT levels with Hb and Hct levels...
October 18, 2016: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://www.readbyqxmd.com/read/27699922/intravenous-iron-and-erythropoiesis-stimulating-agents-in-haemodialysis-a-systematic-review-and-meta-analysis
#12
S D Roger, M Tio, H C Park, H L Choong, B Goh, T R Cushway, V Stevens, I C Macdougall
AIM: Higher dosages of erythropoiesis-stimulating agents (ESAs) have been associated with adverse effects. Intravenous iron is used to optimise ESA response and reduce ESA doses in haemodialysis patients; this meta-analysis evaluates the magnitude of this effect. METHODS: A literature search was performed using MEDLINE, Embase and the Cochrane Collaboration Central Register of Clinical Trials from inception until December 2014, to identify randomised controlled trials (RCTs) of intravenous iron and ESA, in patients undergoing haemodialysis for end-stage kidney disease...
October 3, 2016: Nephrology
https://www.readbyqxmd.com/read/27692637/a-review-of-ferric-pyrophosphate-citrate-triferic-use-in-hemodialysis-patients
#13
Tyler Albright, Akram Al-Makki, Rabih Kalakeche, Brian Shepler
PURPOSE: The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature. METHODS: A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials. FINDINGS: Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations...
September 27, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27661264/protein-based-therapeutic-for-anemia-caused-by-dyserythropoiesis
#14
Jean-Benoît Arlet, Flavia Guillem, Mathilde Lamarque, Michael Dussiot, Thiago Maciel, Ivan Moura, Olivier Hermine, Geneviève Courtois
Major advances have been recently made in understanding the molecular determinants of dyserythropoiesis, particularly due to recent works in β-thalassemia. The purpose of this review is devoted to underline the role of some proteins recently evidenced in the field, that may be new alternative therapeutic targets in the near future to alleviate different types of anemia. Areas covered: This review covers the contemporary aspects of some proteins involved in various types of dyserythropoiesis, including the transcriptional factor GATA-1 and its protective chaperone HSP70, but also cytokines of the transforming growth factor beta (TFG-β) family, TGF-β1 and GDF-11, and hormones as erythroferrone...
October 6, 2016: Expert Review of Proteomics
https://www.readbyqxmd.com/read/27640913/anemia-management-in-cancer-patients-with-chronic-kidney-disease
#15
Andras T Deak, Katharina Troppan, Alexander R Rosenkranz
Anemia is a common complication of cancer and chronic kidney disease (CKD) associated with decreased physical performance as well as poor prognosis for life expectancy. Renal and cancer-induced anemia share common features regarding pathogenesis and therapeutic strategies. It is typically treated with iron substitution, erythropoiesis-stimulating agents (ESA) and in refractory cases with red blood cell transfusions. However, studies of the past few years unveiled numerous setbacks in the use of ESAs. These included a higher risk of cerebrovascular events and increased mortality without the improvement of cardiovascular outcomes in patients with CKD...
September 15, 2016: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/27634442/renoprotection-and-mechanisms-of-erythropoietin-and-its-derivatives-helix-b-surface-peptide-in-kidney-injuries
#16
Yufang Zhang, Weiwei Chen, Yuanyuan Wu, Bin Yang
The renoprotection of erythropoietin (EPO) and its derivatives such as helix B surface peptide (HBSP) have attracted a great deal of attention from scientists and clinicians alike. The evolutional achievement in the dissociation of tissue protection and erythropoiesis is obtained through HBSP characterisation and synthesis. We performed a series of studies using EPO mostly, as well as HBSP, in a variety of biological models subjected to transplant-related renal injuries such as ischemia reperfusion injury (IRI) and/or immunosuppressant nephrotoxicity...
September 9, 2016: Current Protein & Peptide Science
https://www.readbyqxmd.com/read/27595736/activin-receptor-ii-ligand-traps-and-their-therapeutic-potential-in-myelodysplastic-syndromes-with-ring-sideroblasts
#17
Anna Mies, Olivier Hermine, Uwe Platzbecker
Distinct subtypes of lower risk myelodysplastic syndromes display ring sideroblasts in the bone marrow, i. e., erythroid progenitors characterized by excessive iron deposited in the mitochondria. This morphological feature is frequently associated with somatic mutations in components of the splicing machinery that constitutes the underlying molecular principle of the disease. Conventional treatment regimen with erythropoiesis-stimulating agents often fails to induce sustained erythroid improvement in these patients that harbor defects in late-stage erythroblasts downstream of erythropoietin action...
September 5, 2016: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/27557596/iron-deficiency-or-anemia-of-inflammation-differential-diagnosis-and-mechanisms-of-anemia-of-inflammation
#18
Manfred Nairz, Igor Theurl, Dominik Wolf, Günter Weiss
Iron deficiency and immune activation are the two most frequent causes of anemia, both of which are based on disturbances of iron homeostasis. Iron deficiency anemia results from a reduction of the body's iron content due to blood loss, inadequate dietary iron intake, its malabsorption, or increased iron demand. Immune activation drives a diversion of iron fluxes from the erythropoietic bone marrow, where hemoglobinization takes place, to storage sites, particularly the mononuclear phagocytes system in liver and spleen...
October 2016: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27551882/peginesatide-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-an-unfulfilled-promise
#19
Terhi Hermanson, Charles L Bennett, Iain C Macdougall
INTRODUCTION: The introduction of recombinant human erythropoietin revolutionized the management of anemia in patients with chronic kidney disease (CKD). In order to circumvent costly recombinant DNA technology, synthetic chemistry techniques were used to manufacture peginesatide, a synthetic peptide that bore no resemblance to previous erythropoiesis-stimulating agents (ESAs), and yet was capable of stimulating erythropoiesis. Compared with other ESAs, peginesatide was deemed to have advantages related to immunogenicity, administration schedule, and cost...
October 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27521326/trends-in-clinical-investigation-for-myelodysplastic-syndromes
#20
REVIEW
Thomas Prebet, Amer Zeidan
Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are available, and there are many open questions on how to select the most adapted agent and/or sequence of agents in a specific individual...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
keyword
keyword
113834
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"